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Introduction: Rat middle cerebral artery occlusion (MCAO) model is the most commonly used animal model in
ischemic stroke studies. In the model, to increase the amount of stem cells or drugs to enter the brain after delivery
into the internal carotid artery (ICA), the pterygopalatine artery (PPA) is occluded. However, PPA occlusion is a
technically demanding procedure which often causes complications.
Methods: In this study, we developed an ICA injection needle to facilitate easy and efficient delivery of stem cells to
the ischemic brain through the ICA without the need of PPA occlusion. We injected methylene blue and fluorescence
dye DiI-labeled human mesenchymal stem cells (DiI-hMSCs) into the ICA in rats with the ICA injection needle (without
PPA ligation) or the conventional micro-injection needle (with PPA ligation) and assessed their distributions.
Results: When methylene blue was injected, evident blue stains were found in the brain of the injection side particularly
the middle cerebral artery (MCA)-supplied areas but not in the PPA supplied areas. Similarly, when DiI-hMSCs were
injected, the cells largely appeared in the MCA-supplied tissues, which were similar in quantity compared to conventional
micro-injection needle injection with PPA occlusion. Moreover, hMSCs injected with the ICA needle or the micro-injection
needle similarly improved the functional recovery of the infarcted brain.
Conclusions: Our results indicate that the ICA injection needle is easy to use and efficient in delivering cells to the
ischemic brain tissue in rat MCAO model.
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Stroke is a leading cause of death and disability. Stem cells
have demonstrated profound potential in the repair and re-
generation of the injured brain tissue [1]. The therapeutic
effect of stem cells to an injured organ is often associated
with the number of stem cells engrafted. Several routes
have been used to deliver stem cells for brain injuries in
previous studies, such as intravenous injection, intra-
arterial injection and intra-cerebral administration. The
intra-cerebral approach involves complicated and invasive
procedures while the intravascular routes are safer and
more applicable. The intravascular paradigm relies on the
ability of stem cells to migrate toward injured tissues in a
targeted manner, mediated by endogenous chemoattractant* Correspondence: wu.yaojiong@sz.tsinghua.edu.cn
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reproduction in any medium, provided the orand adhesion molecules. Although intravenous administra-
tion is the least invasive and the most convenient route, the
majority of intravenously delivered stem cells are trapped in
the lungs and other organs and do not reach the target
organ [2-4]. Intra-arterial administration bypasses the filter
of the lungs and facilitates a larger number of cells to reach
the target organ. Indeed, it has been shown that intra-
arterial injection leads to a higher and sustained cell
presence at the ischemic site compared to intravenous
administration [5,6].
Rat ischemic stroke models have been used extensively
to evaluate the benefit of stem cells and to study the under-
lying mechanisms. Since ischemic stroke in patients is
mostly caused by the occlusion of the middle cerebral ar-
tery (MCA), intraluminal suture MCA occlusion (MCAO)
has become the most commonly used model in the investi-
gation of stroke in rodents [7]. The reversible MCAO
model has been used widely due to its clinical relevance in
that it mimics recanalization of the thrombosed MCA. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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injected into the internal carotid artery (ICA) for
targeted delivery to the reperfused brain tissue. Because
the pterygopalatine artery (PPA) is a branch of the ICA,
blood in the ICA will shunt into the PPA supplied re-
gion. Therefore, most researchers occluded the PPA
when they performed intra-arterial injection [8]. How-
ever, ligation of the PAA is a difficult procedure because
of the position of this artery [9]. Moreover, occlusion of
the PPA for a long time may cause thrombosis and lead to
severe consequences, such as embolism in MCAO reper-
fusion. Therefore, it is desirable to develop a method to
temporarily occlude the PPA when stem cells or drugs are
delivered into the ICA.
In this study, we developed an ICA injection needle
according to the anatomic features of the ICA and the
PPA. The needle has a closed end to occlude the PPA and
a lateral opening to deliver stem cells into the ICA. We
tested the needle by injecting methylene blue and fluores-
cence dye DiI-labeled human mesenchymal stem cells
(hMSCs) into the ICA in rats and assessing their distribu-
tion. Our results showed that no blue stain was found in
the PPA-supplied regions and similar amounts of DiI-
hMSCs appeared in the MCA-supplied brain tissues com-
pared to the PPA occlusion technique.
Methods
ICA injection needle
The ICA injection needle is similar to a regular syringe
needle, but has several modifications. The needle is 3.0 to
4.0 cm long, with external diameters of 0.3 to 0.5 mm.
The tip of the needle is blunt and closed ended. At 5 mm
from the tip, there is a 27G opening, which serves as the
exit of injected materials through the needle (Figure 1A).
The front segment of the ICA needle is solid, and theFigure 1 The ICA injection needle and anatomy of carotid arteries. (A
carotid artery (CCA), external carotid artery (ECA) and internal carotid artery
to make it straight to the ICA. The ICA injection needle was inserted from t
pterygopalatine artery (PPA).length of the rest of the needle is similar to that of the
conventional needle, so the volume retained in the needle
is almost equal to that in the conventional micro-injection
needle. The size of the needle is selected depending on the
body weight of the rat. For rats weighing 250 to approxi-
mately 270 grams, a 3.5-cm long and 0.4-mm external
diameter needle is appropriate.
The ICA injection needle was designed based on the
anatomic structure of the ICA and the PPA in rats
(Figure 1B-C). In rats, the common carotid artery divides
into the external carotid artery and the ICA at the thyroid
gland level. At about 5 mm from the bifurcation, the ICA
has a branch called the PPA (Figure 1B-C). The trunk and
the branch of the ICA and the PPA form a ‘Y’ shaped
structure. When the ICA injection needle is inserted into
the ICA, this special structure facilitates the closed ended
needle to be easily advanced into the PPA to temporarily
block the blood flow. The external diameter of the needle
is designed to fit the internal diameter of the PPA. The lat-
eral opening of the needle is 5 mm away from the tip. This
distance allows a deep insertion of the needle into the PPA
lumen to sufficiently occlude the blood flow and ensure
the opening is toward the ICA.
The ICA injection needle was inserted into the ICA
from the external carotid artery. First, the external carotid
artery was ligated with a nylon suture and nicked at a 45-
degree angle. Then the external carotid artery was pulled
to make it straight to the ICA (Figure 2A). The needle was
inserted into the external carotid artery, then advanced
into the ICA and further into the PPA and stopped when
an obvious resistance was felt. The ligature was tightened
at the external carotid artery stump until hemostasis was
achieved. Solutions (cells or saline) were infused slowly
through the needle. When completed, the needle was
withdrawn and the external carotid artery stump was) A schematic diagram of the ICA needle. (B) Anatomy of the common
(ICA). (C) After cutting down the distal end of the ECA, pull the ECA
he distal end of the ECA and advanced into the ICA and the
Figure 2 Two insertion routes of the ICA injection needle are shown. (A) Insertion of the ICA injection needle into the internal carotid artery
(ICA) via the external carotid artery (ECA) stump. Pull the ECA to make it straight to the ICA. Insert the needle into the ECA and advance the
needle into the ICA and the pterygopalatine artery (PPA). (B) Insertion of the ICA injection needle into the ICA via the common carotid artery
(CCA). Pull the CCA to make it straight to the ICA. Insert the needle into the CCA and advance the needle into the ICA and the PPA.
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into the ICA from the common carotid artery if the com-
mon carotid artery is pulled to make it straight to the ICA
(Figure 2B).
Animals
Female Sprague–Dawley rats (250 to 270 g, purchased
from the Laboratory Animal Centre, Guangdong Province,
China) were used in the study. Rats were maintained in a
temperature controlled environment (20 ± 1°C) with access
to food and water throughout the experiment. All proce-
dures were performed with the approval of the Animal
Ethics Committee of Tsinghua University.
Middle cerebral artery occlusion and reperfusion in rats
After anesthesia with 10% chloral hydrate (400 mg/kg, in-
traperitoneal (i.p.) injection, Sigma-Aldrich), rats were
subjected to transient focal ischemia for 120 minutes bythe intraluminal suture technique as described previously
[10] with medications. Briefly, the common carotid artery,
external carotid artery and ICA on the left side were care-
fully exposed via a midline cervical incision. The external
carotid artery was ligated with a 4–0 silk suture (10 mm
from the bifurcation), and the common carotid artery was
clamped with a microsurgical clip. A silicon rubber-coated
round-tip nylon surgical thread was inserted into the ICA
(approximately 18 mm from the bifurcation) from the ex-
ternal carotid artery stump to occlude the origin of the
MCA. A silk suture around the external carotid artery was
tightened to prevent bleeding from the puncture site, and
the clip was removed. After 120 minutes of MCAO, reper-
fusion was performed by withdrawing the suture.
Methylene blue injection
Rats were divided into three groups and each group had
four animals. In group 1, the PPA was ligated with a 6–0
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ml, Jiangsu Jumpcan Pharmaceutical Group Co., Ltd.,
Taizhou City, China) was injected with a 30G micro-
injection needle (Hamilton) into the common carotid ar-
tery with preserved flow in the common carotid artery
and ICA. In group 2, 200 μl methylene blue was injected
with the ICA injection needle into the internal carotid
artery. The needle was inserted into the ICA from
the external carotid artery stump and advanced towards
the head of the rat, so the closed-ended needle tip was
inserted into the PPA to occlude the PPA, thus preventing
the methylene blue from entering the PPA, and the
methylene blue was delivered into the ICA via the lateral
opening of the needle thus facilitating its entry into the
brain. In group 3, the ICA was ligated. A total of 200 μl
methylene blue was injected into the PPA with a micro-
injection needle. Rats were scarified immediately after
injection of methylene blue. The skin of the head was
removed to observe the distribution of methylene blue in
facial tissues. Then the brain was exposed to observe the
distribution of methylene blue. Finally, coronal sections
through the brain were cut into seven equally spaced
blocks (2 mm each, including a block of cerebellum) to
examine methylene blue distribution inside the brain.Labeling and transplantation of human mesenchymal
stem cells
Human MSCs were isolated and characterized in our la-
boratory as previously described [11]. Briefly, the re-
search proposal and the procedure of placenta collection
were first approved by the Ethics Committee of Shenzhen
Futian Hospital. Term (38 to 40 weeks gestation) placen-
tas, which were otherwise discarded, were collected from
hospitalized healthy donors with written informed consent.
Placenta tissue was cut into small pieces and enzymatically
digested into a single cell suspension, from which MSCs
adherent to uncoated plastic tissue culture dishes were iso-
lated. The cells were cultivated in a growth medium com-
prising (Dulbecco’s) modified Eagle’s medium ((D)MEM,
Sigma-Aldrich), 10% fetal bovine serum (Gibco) 100 IU
per ml penicillin and 100 μg/ml streptomycin, and pas-
sage 4 to 5 cells were used for xenotransplantation
to rats. To label hMSCs, monolayer hMSCs were incu-
bated with lipophilic fluorochrome 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI,
Sigma-Aldrich) in serum- and phenol-free (D)MEM at
37°C for 45 minutes as previously described [12,13].
Cells were then incubated in the growth medium at 37°C
for one hour, washed with phosphate-buffered saline
(PBS) and harvested for transplantation. Two hours after
MCAO, 1 million DiI-hMSCs in 100 μl PBS were injected
into the ICA in two minutes using three methods: with an
ICA needle without PPA ligation; with a micro-injectionneedle with PPA ligation (the conventional method); or
with a micro-injection needle without PPA occlusion.
Generation of single cell suspensions
Immediately after cell transplantation, the left hemisphere
of the brain of the rats was removed carefully and the cere-
bral tissues were cut into six equally spaced (2 mm) coronal
blocks. Fresh tissues of the third block were weighed,
ground in a cell strainer and washed with a digestion buffer
(0.1% trypsin-ethylenediaminetetraacetic acid (EDTA)) to
generate a single cell suspension. DiI-hMSCs were visual-
ized under a fluorescence microscope and the number of
hMSCs per 104 cells was counted. Thirty microscopic fields
were randomly selected (10 fields/group).
Histological analysis
The left hemisphere of the brain was removed carefully on
day 7 after cell transplantation and the cerebral tissues were
cut into six equally spaced (2 mm) coronal blocks. The
fourth block was fixed in 4% paraformaldehyde (PFA), em-
bedded in optimal cutting temperature compound (OCT)
and cut into 10-μm-thick sections, which included the MCA
perfused territory. Tissue sections were visualized under a
fluorescence microscope for the presence of DiI-hMSCs and
representative fields were photographed. For quantification
of DiI-hMSCs in the ischemic boundary zone, cells positive
for DiI per microscopic field (×200) were counted, and 10
fields per tissue section were randomly selected. Three tissue
sections per sample were examined (n = 4).
Neurological severity scores
Rats were subjected to a modified Neurological Severity
Scores (mNSS) test at 0, 1, 3, 5, 7, 9, 11 and 14 days of
MCAO as described previously [14]. mNSS is a composite
of motor, sensory, reflex and balance tests. In the severity
scores of injury, one point was awarded for the inability to
perform the test or for the lack of a tested reflex; thus, the
higher the score, the more severe was the injury.
Statistical analysis
All data were expressed as mean ± standard deviation
(SD). Results were analyzed using one-way or repeated
measures analysis of variance (ANOVA) with independent
variables of treatment groups and days of testing, followed
by the Bonferroni post-hoc test for multiple comparisons
between treatment groups at each time point. A probabil-
ity (P) value <0.05 was considered significant.Results
Characterization of the ICA injection needle
The ICA injection needle was easily inserted into the ICA
from either the external carotid artery or the common ca-
rotid artery, and then smoothly advanced into the PPA. In
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carotid artery to preserve the blood flow in the common
carotid artery and in the ICA during stem cell transplant-
ation. As the end of the needle is round and smooth, the
procedure did not cause any complications, such as blood
vessel rupture and bleeding.
Distribution of methylene blue
To verify whether PPA was effectively occluded by the
closed end of the ICA injection needle, methylene blue
was injected through the needle. Blue stained tissues were
largely localized to the MCA supplied regions of the brain
[See Additional file 1: Figure S1, n = 4], and no blue stains
were found in PPA supplied areas including tissues aroundFigure 3 Distribution of methylene blue in three injection routes. (A)
micro-injection needle after ligation of the pterygopalatine artery (PPA). (B)
ICA injection needle without ligation of the PPA. (C) Injection of methylenethe eyes, nose and mouth (Figure 3B, n = 4). The dye dis-
tribution pattern was similar to that in animals treated
with ligated PPA and the conventional micro-injection
needle (Figure 3A, n = 4). Conversely, when methylene
blue was injected into the intact PPA, blue stains were
found in the left side of the face including areas around
the eyes, nose and mouth, but no blue stains were found
in the MCA supplied regions of the brain (Figure 3C and
Additional file 1: Figure S1).
Distribution of hMSCs
To further examine whether the ICA injection needle
could efficiently deliver stem cells to the damaged brain
without PPA ligation, we compared the number of DiI-Injection of methylene blue into the internal carotid artery with a
Injection of methylene blue into the internal carotid artery with the
blue into the PPA with a micro-injection needle.
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the brain in rats with MCAO seven days after cell injec-
tion. Similar amounts of DiI-hMSCs were found in the
brain of rats injected with the conventional micro-needle
plus PPA ligation or with the ICA needle without PPA
ligation, but many fewer DiI-hMSCs were found in the
brains of rats injected with a conventional micro-needle
without PPA ligation (Figure 4A and B, P <0.05). To fur-
ther quantify the number of the DiI-hMSCs in the brain,
equal amounts of brain tissues around the infarct (imme-
diately after cell transplantation) were digested into singleFigure 4 MSCs in the brain. Seven days after injection of DiI-hMSCs using
examined under a florescence microscope for the presence of DiI-hMSCs (r
with a micro-injection needle plus PPA ligation; ICA-N, DiI-hMSCs delivered
micro-injection needle without PPA ligation. Nuclei were stained with Hoe
described in the ‘Methods’ (n = 4, *P <0.05). (C) mNSS scores of rats before
were injected one day post MCAO before mNSS evaluation. PBS, injection
*P <0.05. DiI, 1, 1′-dioctadecyl-3, 3, 3′, 3′-tetramethylindocarbocyanine perc
internal carotid artery; MCAO, middle cerebral artery occlusion; mNSS, modcell suspensions, and the number of DiI-positive cells was
counted under a fluorescence microscope [see Additional
file 2: Figure S2, n = 4]. The results are consistent with the
findings in histology (Figure 4A and B).
Neurological outcomes
The severity of neurological defects was evaluated in rats
with MCAO after transplantation of hMSCs using different
methods. Prior to MCAO, mNSS scores indicated that
there was no neurological defect in any of the rats. One
day after MCAO and before MSC transplantation, nothree methods in rats with MCAO, tissue sections of the brain were
ed). (A) Representative images are shown. Mi-N, DiI-hMSCs delivered
with an ICA injection needle; C, PPA, DiI-hMSCs delivered with a
chst (blue). (B) Quantitation of DiI-hMSCs in tissue sections as
and after receiving different treatments at times as indicated. hMSCs
of equal volume of PBS with a micro-injection needle plus PPA ligation.
hlorate; DiI-hMSCs, DiI-labeled human mesenchymal stem cells; ICA,
ified neurology severity score; PPA, pterygopalatine artery.
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the groups (Figure 4C, P >0.05, n = 5). However, at 11 and
14 days post MCAO, rats that had received hMSCs via the
conventional micro-needle plus PPA ligation or the ICA
needle exhibited significant improvement in neurological
function as indicated by the mNSS compared to rats that
received only the PBS injection (Figure 4C, P <0.05, n = 5).
There were no significant differences in mNSS between rats
injected with the conventional micro-needle plus PPA
ligation and rats injected with the ICA needle (Figure 4C,
P> 0.05, n = 5).
Discussion
Rat MCAO models have been the most commonly used
model in stroke studies. To achieve maximum distribution
of stem cells or drugs to the ischemic cerebral tissue after
delivery into the ICA, the PPA is occluded in the model,
although its occlusion is currently considered unnecessary
for the establishment of the MCAO model. Due to tech-
nical difficulties in performing PPA occlusion and subse-
quent complications, the application of the MCAO model
in research has been greatly limited. In this study, we de-
veloped an ICA injection needle which facilitated easy and
efficient delivery of stem cells to the MCAO brain via the
ICA without the need of PPA occlusion.
According to methods for filament insertion in the
MCAO model [10,15], we tested two routes for the inser-
tion of the ICA injection needle. One was from the exter-
nal carotid artery stump, and the other was from the
common carotid artery. From both routes, the ICA injec-
tion needle was easily advanced into the PPA. Of them, in-
sertion from the external carotid artery stump is preferred,
because the blood flow in both the common carotid and
the ICA can be preserved during the entire stem cell trans-
plantation process, and only the external carotid artery re-
mains ligated after surgery. Recent studies indicate that
preservation of the blood flow in the common carotid ar-
tery and the ICA causes minimal changes in cerebral
blood flow during intra-ICA injection and does not cause
thromboembolic complications, thereby greatly minimiz-
ing surgical influences on the animals [8,15,16].
MSCs are multipotent stem cells capable of differenti-
ating into mesoderm- and nonmesoderm-derived tissues
[13,17-19]. They have been identified in a variety of tis-
sues and are likely to participate in the maintenance of
stem cell niches and tissue homeostasis [20,21]. Transplant-
ation of MSCs has been shown to enhance the repair and
regeneration of various tissues including those affected by
strokes [1,22]. Moreover, MSCs have low immunogenicity
and show immune regulatory properties [23]. For these rea-
sons, MSCs are emerging as an extremely promising thera-
peutic agent for a variety of diseases. In this study, we easily
injected hMSCs into the ICA in rats with MCAO and re-
perfusion using the ICA injection needle which temporarilyblocked the blood flow to the PPA, thus facilitating max-
imum entry of the stem cells into the damaged brain. In-
deed, we found similar amounts of DiI-hMSCs in the brain
of rats receiving DiI-hMSCs injected with the ICA injection
needle without PPA ligation which were associated with
similar improvements in neurological function compared
to rats receiving DiI-hMSCs injected with a micro-injection
needle plus PPA ligation. On the same principle, many
other cell types, such as neural stem cells, and drugs can be
delivered with this needle thereby allowing targeted distri-
bution of them to the damaged brain. Moreover, as the
ICA injection needle does not block blood flow in the ICA,
it can be used to deliver cells or drugs into the cerebral vas-
culature without causing cerebral ischemia.
Conclusions
In this study, we developed an ICA injection needle
according to the anatomic features of the ICA and the
PPA. The needle has a closed end to occlude the PPA
and a lateral opening to deliver stem cells into the ICA.
Our data indicate that the needle facilitated easy and ef-
ficient delivery of stem cells into the ICA and further to
the MCA-supplied area of the brain without the need of
PPA ligation, thus avoiding the technical difficulties and
complications seen with PPA ligation.
Additional files
Additional file 1: Figure S1. The distribution of methylene blue in
coronal sections of the brain. (A) Injection of methylene blue into the ICA with
a micro-injection needle after ligation of the PPA. (B) Injection of methylene
blue into the ICA with an ICA injection needle without PPA ligation. (C)
Injection of methylene blue into the PPA with a micro-injection needle.
Additional file 2: Figure S2. hMSCs distribution. 106 DiI-hMSCs were
injected into the left ICA with a micro-injection needle plus PPA ligation
(Mi-N), the ICA injection needle without PPA ligation (ICA-N) or a
micro-injection needle without PPA ligation (PPA) in rats with left MCAO.
Immediately after cell transplantation, a block of the cerebral tissue in the
left MCA-supplied territory per rat was harvested and digested into a single
cell suspension, which was subjected to analysis under a fluorescence
microscope for the presence of DiI-hMSCs (red) in each field. (A) A
representative microscopic field from each group is shown. Nuclei were
stained with Hoechst (blue). (B) Quantitation of DiI-hMSCs in the single cell
suspensions of a given amount of tissue (n = 4).
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